Please login to the form below

Not currently logged in

Trial sets up showdown between Ibrance and Novartis' ribociclib

Positive interim data could put the Swiss firm's breast cancer therapy in-line for early approval


Novartis has halted a phase III trial of its CDK 4/6 inhibitor ribociclib early after the drug met its objectives, putting an early approval for the drug on the table.

An interim look at the data showed ribociclib achieved the goal of a significant increase in progression-free survival (PFS) in breast cancer, and Novartis now says it will start talking to regulators about regulatory filings.

Approval would make ribociclib the first direct competitor to Pfizer's first-in-class CDK 4/6 inhibitor Ibrance (palbociclib), which has been growing at a phenomenal pace since its approval last year and achieved first-quarter 2016 sales of $429m.

The results of the MONALEESA-2 trial showed that ribociclib (LEE011) given in combination with Novartis' hormone therapy Femara (letrozole) extended PFS compared to letrozole alone in postmenopausal women with previously-untreated hormone receptor positive (HR+), HER-2 negative advanced breast cancer.

While PFS data may support approval Novartis is continuing to follow-up patients in the study to see if its drug also has an impact on overall survival.

Ibrance is approved alongside Femara for the same patient population, so ribociclib will compete head-to-head in the market if regulators approve the drug, with another candidate (abemaciclib) from Eli Lilly also in late-stage testing.

Novartis' chief medical officer Vasant Narasimhan said recently that the company expects ribociclib to "capture a significant portion in a three-player market".

The company also indicated that it will be evaluating expanded access programmes in some regions to help ensure women who may benefit from ribociclib have access to the drug.

If approved, ribociclib will slot into Novartis' portfolio alongside Femara and also mTOR inhibitor Afinitor/Votubia (everolimus), which is also approved for HR+/HER2- breast cancer amongst other indications and brought in $1.6bn in sales last year.

The arrival of Ibrance on the market has pegged back Afinitor's growth and pushed it to later-line use, although the company believes many breast cancer patients will still end up receiving the drug.

Novartis is also testing ribociclib in combination with AstraZeneca's hormonal therapy Faslodex (fulvestrant) in the MONALEESA-3 study - due to generate results in 2018 - and is looking into possible combinations with its PI3 kinase delta inhibitors BYL719 and buparlisib (BKM120).

Article by
Phil Taylor

19th May 2016

From: Research



Featured jobs

Subscribe to our email news alerts


Add my company
Weber Shandwick

At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...